Role of telomerase in anticancer activity of pristimerin in prostate cancer cells
Liu YB, Gao X, Deeb D, Pindolia K, Gautam SC. Role of telomerase in anticancer activity of pristimerin in prostate cancer cells. J Exp Ther Oncol. Sep 2017;11(1):41-49.
Journal of experimental therapeutics & oncology
Pristimerin (PM) is a quinonemethide triterpenoid present in various plant species with strong antiprolifertive and proapoptotic activities in cancer cells. The effect of PM on telomerase which is reactivated in most cancers including carcinoma of the prostate (CaP) has not been studied. We investigated the effect of PM on the expression of human telomerase reverse transcriptase (hTERT) gene that codes for the catalytic subunit of the telomerase holoenzyme complex in prostate cancer cell lines LNCaP and PC-3 cells. The inhibition of cell proliferation and induction of apoptosis by PM in both cell lines was associated with the inhibition of hTERT mRNA expression, suppression of native and phosphorylated hTERT protein and hTERT telomerase activity. The ablation of hTERT expression increased the sensitivity of cancer cells to PM. In addition, results also revealed that the inhibition of hTERT expression is attributed to the inhibition of transcription factors SP1, c-Myc and STAT3 and protein kinase B/Akt which regulate hTERT transcriptionally and post-translationally, respectively. These data provide evidence that telomerase is a potential target of PM in prostate cancer.
Medical Subject Headings
Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Male; Phosphorylation; Prostatic Neoplasms; RNA Interference; RNA, Messenger; Signal Transduction; Telomerase; Transcription, Genetic; Transfection; Triterpenes